X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership will support current Good Manufacturing Practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine), a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector platform.
Lead Product(s): MVA-based SARS-CoV-2 Vaccine
Therapeutic Area: Oncology Product Name: GEO-CM04S1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Advanced Bioscience laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 31, 2023
Details:
GEO-CM04S1 is a synthetic attenuated modified vaccinia Ankara (sMVA) vector vaccine that expresses spike and nucleocapsid antigens of the SARS-CoV-2 (COVID-19) virus.
Lead Product(s): GEO-CM04S1
Therapeutic Area: Infections and Infectious Diseases Product Name: GEO-CM04S1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: EmVenio Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2023
Details:
Gedeptin (Ad/PNP) is a gene-directed enzyme prodrug therapy (GDEPT) that results in the formation of the oncolytic agent within the tumor itself, resulting in tumor cell death while significantly limiting systemic exposure.
Lead Product(s): Ad/PNP,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Gedeptin
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical trial.
Lead Product(s): COH04S1
Therapeutic Area: Infections and Infectious Diseases Product Name: COH04S1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: City of Hope
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
GeoVax’s vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented efficacy and immunogenicity data for the Company’s lead vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins.
Lead Product(s): GEO-CM02
Therapeutic Area: Infections and Infectious Diseases Product Name: GEO-CM02
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
The Patent License Agreement to GeoVax includes access to NIAID’s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.
Lead Product(s): GEO-CM01
Therapeutic Area: Infections and Infectious Diseases Product Name: GEO-CM01
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 26, 2020
Details:
The study demonstrated that guinea pigs vaccinated with GeoVax’s developmental MVA-MARV-VLP vaccine were 100% protected against death and disease caused by the Angola strain of Marburg virus.
Lead Product(s): MVA-MARV-VLP vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
GeoVax is using its GV-MVA-VLPTMvaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2020
Details:
An independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV infection.
Lead Product(s): GOVX-B11
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
